Purpose
To determine the in vivo elastic modulus of the human cornea using vibrational optical coherence tomography (VOCT).
Methods
Vibrational analysis coupled with optical coherence tomography (OCT) was used to obtain the resonant frequency (RF) and elastic modulus of corneal structural components. VOCT corneal thickness values were measured using OCT images and correlated with corneal thickness determined with Pentacam (Oculus, Wetzlar, Germany). Moduli were obtained at two locations: central cornea (CC) and inferior cornea (IC). Measurements were obtained with and without anesthetic eye drops to assess their effect on the modulus measurements.
Results
VOCT thickness values correlated positively (
R
2
= 0.97) and linearly (y = 1.039x–16.89) with those of Pentacam. Five RF peaks (1–5) were present, although their presence was variable across eyes. The RF for peaks 1 to 5 in the CC and IC ranged from 73.5 ± 4.9 to 239 ± 3 Hz and 72.1 ± 6.3 to 238 ± 4 Hz, respectively. CC and IC moduli for peaks 1 to 5 ranged from 1.023 ± 0.104 to 6.87 ± 0.33 MPa and 0.98 ± 0.15 to 6.52 ± 0.79 MPa, respectively. Topical anesthesia did not significantly alter the modulus (
P
> 0.05 for all), except for peak 2 in the CC (
P
< 0.05).
Conclusions
This pilot study demonstrates the utility of VOCT as an in vivo, noninvasive technology to measure the elastic modulus in human corneas. The structural origin of these moduli is hypothesized based on previous reports, and further analyses are necessary for confirmation.
Translational Relevance
This work presents VOCT as a novel approach to assess the in vivo elastic modulus of the cornea, an indicator of corneal structural integrity and health.
Isolated from
Streptomyces caespitosus
, mitomycin C (MMC) has various applications in the management of corneal and external disease due to its ability to modulate cellular proliferation. It has been employed in pterygium surgery, ocular surface neoplasia, and refractive surgery. Currently, there is no definite consensus on the treatment protocols for each of the aforementioned applications. Although its benefits in the management of corneal and external diseases are promising, MMC use has potential complications including endothelial cell loss, corneal perforation, scleral melt, secondary glaucoma, iritis, and endophthalmitis. This article will review the literature regarding the use of MMC in the field of cornea and external disease and describe protocols employed with corresponding outcomes.
Purpose:
This study aimed to characterize cornea-centered clinical trials, completed before 2020, registered on ClinicalTrials.gov and identify discrepancies in publication.
Methods:
ClinicalTrials.gov, a database from the National Institutes of Health, was queried to identify registered cornea-related clinical trials. Trials were included if they were interventional and completed before January 1, 2020. ClinicalTrials.gov, PubMed.gov, and Google Scholar were then searched to evaluate publications from the trial. Data collected for each trial included sponsor, intervention type, phase, dry eye focus, and location of the principal investigator.
Results:
A total of 520 trials were included in the final analysis. Of all studies, 270 (51.9%) were found to have published results. Industry-sponsored studies were associated with drug intervention trials, dry eye focus, and the principal investigator's location within the United States (P < 0.05 for all). Nonindustry sponsors were associated with device and procedure intervention trials (P < 0.05 for both). Overall, trials that were categorized as procedure interventions were published at a significantly higher rate than other interventional categories (64.2% vs. 50.1%; P = 0.03). Subgroup analysis revealed that among nonindustry studies, late-phase trials and procedural-based trials were published at a significantly higher rate compared with other studies (67.2% vs. 51.6%; P = 0.04 and 67.8% vs. 51.6%; P = 0.03).
Conclusions:
Only 51.9% of registered interventional cornea-based clinical trials result in publications in the peer-reviewed literature, highlighting potential publishing discrepancies.
The purpose of this publication is to report a child with choroidal metastasis from a primary lung carcinoid tumor treated with 125-iodine plaque brachytherapy while achieving complete tumor regression. A 15-year-old girl with a history of stage IV lung carcinoid tumor developed painless progressive visual loss in her right eye. Ophthalmological exam documented a unilateral solitary large choroidal mass with complete exudative retinal detachment. Planned palliative treatment with plaque brachytherapy was performed utilizing a total dose of 45 Gy to the tumor apex. No tumor regression was noted after 6 months of follow-up. Ten months after primary therapy, re-treatment with a total dose of 90 Gy to the tumor apex was performed due to tumor progression. Complete regression was achieved after secondary treatment without evidence of recurrence after 18 months of follow-up. In conclusion, high-dose plaque brachytherapy may induce complete tumor regression in select adolescent patients with choroidal metastasis from lung carcinoid tumor.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.